• Image of a researcher pipetting

    The multi-target stool (mt-sDNA) test in a non-invasive, at-home colorectal cancer (CRC) screening tool that identifies molecular markers associated with cancer cells in stool samples.1 It is an effective screening tool for patients of any gender, age 45+, and at average risk of developing CRC.1,2  Learn more about how a positive mt-sDNA result may indicate the presence of CRC or Advance Adenoma (AA) and the process for sample collection.

    Learn more
  • Image of an individual looking over charts and graphs

    Two studies evaluated the performance and specificity of screening with mt-sDNA as a tool to detect CRC in patients at average risk: DeeP-C2  (asymptomatic, average-risk adults, ages 50-84) and Act Now3 (average-risk adults, ages 45-49). Learn more about the data supporting mt-sDNA screening.

    Learn more
  • Image of people sitting in a queue

    Real-world data demonstrates that mt-sDNA is an effective modality for CRC screening in diverse clinical practice.4 It has high adherence rates5,6 and has been shown to be cost effective.7 Learn more about mt-sDNA testing performance in real-world settings.

    Learn more
  • Image of a stethoscope and data tables

    Cancer models are an important tool to help understand the value of healthcare interventions where research is not ethical or feasible.8 Learn more about the models used in CRC screening decision-making.9

    Learn more
Learn more about the full Indications/Contraindications for the mt-sDNA test. Please see complete prescribing information for mt-sDNA in the Cologuard Physician Brochure.

References

Cologuard Physician Brochure. Exact Sciences Corporation. Madison, WI.

Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370(14):1287-1297.

Imperiale TF, Kisiel JB, Itzkowitz SH, et al. Specificity of the multi-target stool DNA Test for colorectal cancer screening in average-risk 45-49 year-olds: a cross-sectional study. Cancer Prev Res. 2021;14(4):489-496.

Anderson JC, Robinson CM, Hisey WM, et al. Colorectal neoplasia detection in individuals with positive multitarget stool DNA tests: data from the New Hampshire Colonoscopy Registry. J Clin Gastroenterol. 2021.

Weiser E, Parks PD, Swartz RK, et al. Cross-sectional adherence with the multi-target stool DNA test for colorectal cancer screening: real-world data from a large cohort of older adults. J Med Screen. 2021;28(1):18-24.

 6 Prince M, Lester L, Chiniwala R, Berger B. Multitarget stool DNA tests increases colorectal cancer screening among previously noncompliant  Medicare patients. World J Gastroenterol. 2017;23(3):464-471.

 Ladabaum U, Mannalithara A. Comparative effectiveness and cost effectiveness of a multi-target stool DNA test to screen for colorectal neoplasia. Gastroenterol. 2016;151(3):427-439.e6.

MapleHealth workshop on health economic and outcomes research. November 8, 2019.

National Cancer Institute. CISNET modeling approach. Accessed December 10, 2021. https://cisnet.cancer.gov/modeling/index.html


Last Updated: 3/1/2022

We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.

Accept